NAS:ALRN (USA) Also trade in: Germany

Aileron Therapeutics Inc

$ 0.87 -0.02 (-1.7%)
Volume: 53,163 Avg Vol (1m): 140,390
Market Cap $: 23.11 Mil Enterprise Value $: 9.84 Mil
P/E (TTM): 0.00 P/B: 1.01
Earnings Power Value 0
Net Current Asset Value 0.33
Tangible Book 0.87
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
62.34% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ALRN: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
N/A
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -12.74
DISTRESS
GREY
SAFE

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -117.79
ROE ranked lower than
92.72% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ALRN: -117.79
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -117.79, Med: -93.62, Max: -93.62
Current: -117.79
-117.79
-93.62
ROA % -86.95
ROA ranked lower than
74.72% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ALRN: -86.95
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -216.8, Med: -102.83, Max: -60.51
Current: -86.95
-216.8
-60.51
ROC (Joel Greenblatt) % -837.51
ROC (Joel Greenblatt) ranked lower than
74.90% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ALRN: -837.51
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -17630.65, Med: -5803.36, Max: -837.51
Current: -837.51
-17630.65
-837.51
3-Year Total EBITDA Growth Rate -36.10
3-Year EBITDA Growth Rate ranked lower than
100.00% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ALRN: -23.2
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A

» ALRN's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ALRN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XCNQ:CRZ NAS:BDSI NAS:AFMD NAS:GNMX TSE:6090 XKRX:011000 NAS:ORGS NAS:OTIC XKRX:067370 TPE:1734 OSTO:CELLNK B XPAR:ADVIC TSE:2370 XKRX:220250 OTCPK:CNBX NAS:FLKS NAS:ZYNE TSE:2191 NAS:COCP XSWX:SANN
Traded in other countries 015.Germany
Address 281 Albany Street, Cambridge, MA, USA, 02139
Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing and commercializing a novel class of therapeutics called stapled peptides. Its lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers. ALRN-6924, reactivates p53-mediated tumor suppression by targeting the two primary p53 suppressor proteins, MDMX and MDM2.

Ratios

Current vs industry vs history
PB Ratio 1.01
PB Ratio ranked higher than
90.54% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ALRN: 1.01
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 9.07
Current: 1.01
0
9.07
EV-to-EBIT -0.30
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ALRN: -0.3
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -13.82, Med: 0, Max: 0.58
Current: -0.3
-13.82
0.58
EV-to-EBITDA -0.30
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ALRN: -0.3
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -13.92, Med: 0, Max: 0.58
Current: -0.3
-13.92
0.58
Current Ratio 3.11
Current Ratio ranked higher than
59.59% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ALRN: 3.11
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.58, Med: 5.18, Max: 11.57
Current: 3.11
1.58
11.57
Quick Ratio 3.11
Quick Ratio ranked higher than
61.45% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ALRN: 3.11
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.58, Med: 5.18, Max: 11.57
Current: 3.11
1.58
11.57

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -10.50
3-Year Share Buyback Rate ranked lower than
100.00% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ALRN: -10.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
N/A

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.00
Price-to-Tangible-Book ranked higher than
92.73% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ALRN: 1
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.63, Med: 2.68, Max: 3.33
Current: 1
0.63
3.33
Earnings Yield (Joel Greenblatt) % -319.85
Earnings Yield (Greenblatt) ranked lower than
100.00% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ALRN: -319.85
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -175591.44, Med: 0, Max: 88711.15
Current: -319.85
-175591.44
88711.15

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N